To Market, To Market – 2005

@article{Hegde2006ToMT,
  title={To Market, To Market – 2005},
  author={Shridhar. Hegde and Michelle A. Schmidt},
  journal={Annual Reports in Medicinal Chemistry},
  year={2006},
  volume={41},
  pages={439-477}
}
Publisher Summary This chapter discusses 22 new chemical entities (NCEs) and two new biological entities (NBEs) manufactured in the year 2005. In the anti-infective therapeutic area five new drugs were introduced—Tygacil™ (tigecycline), Aptivus ® (tipranavir), Ebernets (eberconazole), Lulicon ® (luliconazole), and Finibax (doripenem). In the area of the central nervous system (CNS), there are five marketed drugs—Prialt ® (ziconotide), Prexige ® (lumiracoxib), Lunesta™ (eszopiclone), Rozerem… Expand
Chapter 32 To Market, To Market – 2006
TLDR
This chapter describes 27 new molecular entities (NMEs) for therapeutic use, including five first-in-class drugs which were manufactured in the year 2007, which included eight NMEs and the vaccine for cervical cancer that are Merck's Gardasil®, Sutent® (sunitinib), Sprycel™ (dasatinib), Zolinza™ (vorinostat) and Dacogen™ (decitabine). Expand
Major Drug Introductions
TLDR
Anti-infectives, anti-cancer drugs, drugs for cardiovascular disease, diseases of the nervous system, diabetes and antirheumatics are dominant in the therapeutic areas for which they were initially introduced. Expand
Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study
TLDR
The time between approval and first PMSE was shorter for drugs with an FDA REMS, and this finding may contribute to improved awareness of the risk/benefit balance required to ensure continued safe and effective use of new drugs. Expand
Prodrugs: Some thoughts and current issues.
  • V. Stella
  • Medicine
  • Journal of pharmaceutical sciences
  • 2010
TLDR
The prodrug approach to resolving formulation, delivery, and toxicity limitations on problematic drugs has had its proponents and detractors, and is becoming an integral part of the drug discovery paradigm in some large pharma companies. Expand
Introduction and geographic availability of new antibiotics approved between 1999 and 2014
TLDR
Great variation in geographic availability of antibiotics is shown, indicating that availability in multiple regions and country income classes is possible, but rarely seen within a few years of market authorization. Expand
Prodrug strategies to overcome poor water solubility.
TLDR
This review explores the use of pro drug interventions to effect improved oral and parenteral delivery of poorly water-soluble problematic drugs, using both marketed as well as investigational prodrugs as examples. Expand
Opportunities and Challenges in the Discovery of New Central Nervous System Drugs
TLDR
A perspective on both the opportunities and challenges in the discovery and development of novel medicines for the treatment of human CNS disorders is provided. Expand
Identification of a Novel Protein Synthesis Inhibitor Active against Gram‐Positive Bacteria
TLDR
The identification of a benzothiazolium salt, ABTZ‐1, that displayed potent antibacterial activity against Gram‐positive pathogens and represents a promising new class of antibacterial agents. Expand
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
TLDR
This paper is a comprehensive overview of the scientific efforts made to develop novel antileukemia therapeutics by presenting chemical, pharmacological, and pharmacogenomic data obtained during preclinical and clinical assessment of these agents. Expand
Efficient synthesis and resolution of novel 2-(hydroxymethyl)-7,8-dihydro-1H-indeno[5,4-b] furan-6(2H)-one by lipase Pseudomonas cepacia
Abstract Lipase Pseudomonas cepacia catalyzed acylation of (±)-2-(hydroxymethyl)-7,8-dihydro-1H-indeno[5,4-b] furan-6(2H)-one using vinyl acetate as the acyl donor in acetone gaveExpand
...
1
2
...

References

SHOWING 1-10 OF 87 REFERENCES
Chapter 33. To market, to market - 2002
TLDR
A significant increase in the number of NCEs and NBEs was observed in 2002, and with eight new launches, antiinfectives were the most active therapeutic area. Expand
Tipranavir: A novel nonpeptidic protease inhibitor
If approved, tipranavir (Boehringer Ingelheim) will be the ninth protease inhibitor (PI) available and the first nonpeptidic PI available in the United States. Designed by structure-based analysis,Expand
Six Novel Antimycotics
TLDR
Six new antimycotic agents which have potential applications for human cutaneous and mucosal diseases are reviewed, including rilopirox, lanoconazole, NND-502, butenafine, eberconazole and voriconazole. Expand
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
TLDR
Doripenem appears to be a potent carbapenem with a spectrum resembling currently marketed antipseudomonalcarbapenems, but with greater activity when tested against some non-fermentative bacillary strains. Expand
Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.
TLDR
Crystallographic studies provided further information on important binding interactions responsible for high enzymatic binding and led to compound VI, which inhibits HIV protease with a Ki value of 8 pM and shows an IC90 value of 100 nM in antiviral cell culture. Expand
Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor.
Efforts to develop therapeutically relevant HIV protease inhibitors as medicinal agents in confronting the AIDS crisis have been aided by the wealth of fundamental information acquired during relatedExpand
Nepafenac, a Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: I. Assessment of Anti-Inflammatory Efficacy
TLDR
Nepafenac's inhibitory efficacy and longer duration of action was confirmed in a trauma-induced rabbit model of acute ocular inflammation monitoring protein or PGE2 accumulation in aqueous humor and results warrant further assessment of nepafanac's topical ocular efficacy in the treatment of postoperative ocular pain, inflammation, and posterior segment edema. Expand
A review of entecavir in the treatment of chronic hepatitis B infection
  • A. Rivkin
  • Medicine
  • Current medical research and opinion
  • 2005
TLDR
Entecavir, a new deoxyguanosine analog, represents a third agent within the nucleoside/nucleotide HBV polymerase inhibitor class with distinct advantages over lamivudine and adefovir dipivoxil, and is the most potent inhibitor of HBV DNA polymerase. Expand
Practical Perspectives on the Use of Tipranavir in Combination With Other Medications: Lessons Learned From Pharmacokinetic Studies
TLDR
This review summarizes the pharmacokinetic interactions between tipranavir/ritonavir and 11 other antiretroviral medications and between tip Ranavir /ritonvir and drugs used to treat opportunistic infections such as fungal infections, antireTroviral‐treatment‐related conditions such as hyperlipidemia, and side effects such as diarrhea. Expand
Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor
TLDR
Clinical studies support a once-daily dosing regimen of lumiracoxib, a novel COX-2 selective inhibitor with improved biochemical selectivity over that of currently available coxibs, which is structurally distinct from other drugs in the class and has weakly acidic properties. Expand
...
1
2
3
4
5
...